Heart failure Drug's biomarker effects scrutinized in japanese patients
NCT ID NCT07527767
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used blood and urine samples from 236 Japanese patients with chronic heart failure to see how biomarkers like BNP change during treatment with sacubitril valsartan or enalapril. Researchers looked for links between biomarker changes and improvements in heart failure symptoms. The goal was to better understand how these drugs work in this specific population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacubitril valsartan
- What this could lead to
- If successful, this could help doctors better understand how sacubitril valsartan affects heart failure biomarkers, potentially improving treatment monitoring.
- What could go wrong
- This is a secondary analysis of existing data, not a new treatment trial. The findings may not lead to direct changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION (HFREF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative SIte
Tokyo, Tokyo, 105-6333, Japan